INCY

$120.393.07%3.59

Nachbörslich: 120.41+0.02 +0.02%

Incyte Corp (INCY)

Date: O: H: L: C: Vol:

Schlusskurs vom Vortag:

$116.80

Offen:

$120.10

24-Stunden-Volumen:

2,840,219

Relatives Volumen:

1.43

Marktkapitalisierung:

$24.40B

Einnahmen:

$5.36B

Nettoeinkommen (Verlust:

$1.43B

KGV:

17.02

EPS:

$7.07

Netto-Cashflow:

$1.42B

1W Leistung:

+4.04%

1M Leistung:

-0.79%

6M Leistung:

+26.37%

1Y Leistung:

+30.02%

1-Tages-Spanne:

$119.55$122.87

1-Wochen-Bereich:

$111.01$122.87

52-Wochen-Spanne:

$89.25$132.60

Incyte Corp Aktie (INCY) Unternehmensprofil

Firmenname

Incyte Corp

Sektor

Healthcare

Branche

Biotechnology

Telefon

(302) 498-6700

Adresse

1801 AUGUSTINE CUT-OFF, WILMINGTON, DE, USA

Mitarbeiter

2,844

@Incyte

Nächster Verdiensttermin

null

Neueste SEC-Einreichungen

SEC

INCY-Diskussionen auf X

INCY vs. VRTX, REGN, MRNA, ARGX, ONC vergleichen

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
INCY Incyte Corp	$120.39	$24.40B	$5.36B	$1.43B	$1.42B	$7.07
VRTX Vertex Pharmaceuticals Inc	$558.88	$141.65B	$12.34B	$4.34B	$3.71B	$16.87
REGN Regeneron Pharmaceuticals Inc	$927.89	$95.53B	$14.92B	$4.42B	$3.79B	$41.04
MRNA Moderna Inc	$221.72	$88.52B	$2.23B	-$3.19B	-$1.60B	-$8.15
ARGX Argen X Se Adr	$892.87	$56.15B	$4.16B	$1.29B	$734.26M	$19.58
ONC Beone Medicines Ltd Adr	$370.33	$41.89B	$5.76B	$514.49M	$1.10B	$4.48

Incyte Corp Aktie (INCY) Hochstufungen & Herabstufungen

Datum	Aktion	Analytiker	Ratingänderung
2026-10-20	Resumed	Morgan Stanley	Equal-Weight
2026-08-20	Eingeleitet	Canaccord Genuity	Buy
2026-06-22	Hochstufung	BMO Capital Markets	Underperform → Market Perform
2026-05-22	Eingeleitet	Bernstein	Mkt Perform
2026-03-16	Herabstufung	Jefferies	Buy → Hold
2026-02-05	Eingeleitet	H.C. Wainwright	Buy
2026-01-20	Herabstufung	Wells Fargo	Overweight → Equal Weight
2025-12-08	Hochstufung	Mizuho	Neutral → Outperform
2025-11-03	Hochstufung	Guggenheim	Neutral → Buy
2025-10-08	Herabstufung	Oppenheimer	Outperform → Perform
2025-08-06	Hochstufung	Wells Fargo	Equal Weight → Overweight
2025-08-01	Eingeleitet	Barclays	Overweight
2025-06-16	Hochstufung	Stifel	Hold → Buy
2025-03-18	Herabstufung	Guggenheim	Buy → Neutral
2025-03-18	Herabstufung	William Blair	Outperform → Mkt Perform
2024-12-17	Eingeleitet	UBS	Neutral
2024-10-29	Hochstufung	BofA Securities	Neutral → Buy
2024-10-01	Eingeleitet	Wolfe Research	Outperform
2024-09-18	Herabstufung	Truist	Buy → Hold
2024-07-02	Herabstufung	BMO Capital Markets	Market Perform → Underperform
2024-05-23	Eingeleitet	Deutsche Bank	Hold
2024-04-23	Eingeleitet	Cantor Fitzgerald	Neutral
2024-02-23	Eingeleitet	Jefferies	Buy
2024-02-14	Herabstufung	JMP Securities	Mkt Outperform → Mkt Perform
2023-12-13	Hochstufung	Leerink Partners	Market Perform → Outperform
2023-12-04	Hochstufung	Guggenheim	Neutral → Buy
2023-11-21	Herabstufung	Goldman	Buy → Neutral
2023-07-25	Eingeleitet	Citigroup	Buy
2023-05-04	Herabstufung	BofA Securities	Buy → Neutral
2023-04-10	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2023-03-24	Hochstufung	SVB Securities	Underperform → Market Perform
2023-01-31	Eingeleitet	Piper Sandler	Overweight
2022-08-03	Herabstufung	Evercore ISI	Outperform → In-line
2022-08-03	Herabstufung	Guggenheim	Buy → Neutral
2022-07-28	Eingeleitet	Wells Fargo	Equal Weight
2022-02-09	Herabstufung	SVB Leerink	Mkt Perform → Underperform
2022-01-18	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2021-11-19	Eingeleitet	BMO Capital Markets	Market Perform
2021-07-20	Hochstufung	The Benchmark Company	Hold → Buy
2021-02-10	Herabstufung	SVB Leerink	Mkt Perform → Underperform
2021-01-07	Eingeleitet	Truist	Buy
2021-01-04	Hochstufung	Guggenheim	Neutral → Buy
2020-06-16	Eingeleitet	The Benchmark Company	Hold
2020-05-06	Herabstufung	JP Morgan	Overweight → Neutral
2020-04-29	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2020-04-01	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2020-03-24	Resumed	William Blair	Outperform
2020-03-13	Hochstufung	BofA/Merrill	Neutral → Buy
2020-02-04	Resumed	BofA/Merrill	Neutral
2020-01-03	Bestätigt	BMO Capital Markets	Market Perform
2020-01-03	Herabstufung	Mizuho	Buy → Neutral
2020-01-02	Herabstufung	Guggenheim	Buy → Neutral
2019-10-03	Eingeleitet	Mizuho	Buy
2019-09-12	Eingeleitet	BMO Capital Markets	Market Perform
2019-09-05	Hochstufung	JMP Securities	Mkt Perform → Mkt Outperform
2019-09-05	Resumed	Morgan Stanley	Equal-Weight
2019-09-05	Hochstufung	Oppenheimer	Perform → Outperform
2019-05-21	Eingeleitet	Credit Suisse	Neutral
2019-05-03	Herabstufung	Barclays	Overweight → Equal Weight
2019-04-11	Eingeleitet	Stifel	Hold
2019-04-03	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2019-01-24	Hochstufung	William Blair	Mkt Perform → Outperform

Finanzdaten der Incyte Corp-Aktie (INCY)

Umsatz

Nettogewinn

Free Cashflow

ENV

Incyte Corp-Aktie (INCY) Insiderhandel

PABLO CAGNONIOct 15 '26
Officer
Transaktion
Proposed Sale
Kosten
$112.71
#Aktien
2,642
Wert ($)
297,780
#Aktien Gesamt
0
CAGNONI PABLO JOct 15 '26
President, Global Head of R&D
Transaktion
Sale
Kosten
$112.71
#Aktien
2,642
Wert ($)
297,780
#Aktien Gesamt
183,200
CAGNONI PABLO JSep 15 '26
President, Global Head of R&D
Transaktion
Sale
Kosten
$120.49
#Aktien
23,218
Wert ($)
2,797,629
#Aktien Gesamt
183,200
PABLO CAGNONISep 15 '26
Officer
Transaktion
Proposed Sale
Kosten
$120.49
#Aktien
23,218
Wert ($)
2,797,571
#Aktien Gesamt
0
CAGNONI PABLO JSep 15 '26
President, Global Head of R&D
Transaktion
Option Exercise
Kosten
$66.39
#Aktien
23,218
Wert ($)
1,541,331
#Aktien Gesamt
206,418
PABLO CAGNONIAug 19 '26
Officer
Transaktion
Proposed Sale
Kosten
$125.56
#Aktien
10,801
Wert ($)
1,356,190
#Aktien Gesamt
0
CAGNONI PABLO JAug 19 '26
President, Global Head of R&D
Transaktion
Sale
Kosten
$125.56
#Aktien
10,801
Wert ($)
1,356,174
#Aktien Gesamt
183,200
PABLO CAGNONIAug 12 '26
Officer
Transaktion
Proposed Sale
Kosten
$120.04
#Aktien
10,803
Wert ($)
1,296,774
#Aktien Gesamt
0
CAGNONI PABLO JAug 12 '26
President, Global Head of R&D
Transaktion
Sale
Kosten
$120.04
#Aktien
10,803
Wert ($)
1,296,792
#Aktien Gesamt
194,001
PABLO CAGNONIAug 05 '26
Officer
Transaktion
Proposed Sale
Kosten
$122.69
#Aktien
10,640
Wert ($)
1,305,450
#Aktien Gesamt
0

Insiderhandel	Beziehung	Datum	Transaktion	Kosten	#Aktien	Wert ($)	#Aktien Gesamt
PABLO CAGNONI	Officer	Oct 15 '26	Proposed Sale	$112.71	2,642	297,780	0
CAGNONI PABLO J	President, Global Head of R&D	Oct 15 '26	Sale	$112.71	2,642	297,780	183,200
CAGNONI PABLO J	President, Global Head of R&D	Sep 15 '26	Sale	$120.49	23,218	2,797,629	183,200
PABLO CAGNONI	Officer	Sep 15 '26	Proposed Sale	$120.49	23,218	2,797,571	0
CAGNONI PABLO J	President, Global Head of R&D	Sep 15 '26	Option Exercise	$66.39	23,218	1,541,331	206,418
PABLO CAGNONI	Officer	Aug 19 '26	Proposed Sale	$125.56	10,801	1,356,190	0
CAGNONI PABLO J	President, Global Head of R&D	Aug 19 '26	Sale	$125.56	10,801	1,356,174	183,200
PABLO CAGNONI	Officer	Aug 12 '26	Proposed Sale	$120.04	10,803	1,296,774	0
CAGNONI PABLO J	President, Global Head of R&D	Aug 12 '26	Sale	$120.04	10,803	1,296,792	194,001
PABLO CAGNONI	Officer	Aug 05 '26	Proposed Sale	$122.69	10,640	1,305,450	0

Incyte Corp Aktie (INCY) Neueste Nachrichten

Oct 27, 2026

MTAK Price Today: Market Technology Acquisition Corp. Stock Price, Quote & Chart | MEXC - MEXC

Oct 27, 2026

Oct 26, 2026

Incyte & Genmab Collaborate to Develop a New Colorectal Cancer Therapy - Zacks Investment Research

Oct 26, 2026

An experimental drug combination showed a 71% response rate in colorectal cancer. - Stock Titan

Oct 26, 2026

Oct 22, 2026

Incyte Corp. Company & People | INCY - Barron's

Oct 22, 2026

Oct 18, 2026

Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 - Via TT

Oct 18, 2026

Oct 14, 2026

Incyte plans to publish third-quarter results at 7 a.m. Oct. 29, then hold a call at 8. - Stock Titan

Oct 08, 2026

Oct 07, 2026

Incyte Corporation (INCY) Stock Forecasts - Yahoo Finance

Oct 07, 2026

Oct 02, 2026

Incyte Corp. Stock Grades | INCY - Barron's

Oct 02, 2026

Form 4 Incyte Corporation For: 2 October By Investing.com - Investing.com Canada

Oct 02, 2026

Oct 01, 2026

Q2 Earnings Roundup: Incyte (NASDAQ:INCY) And The Rest Of The Biotechnology Segment - Yahoo Finance

Oct 01, 2026

Sep 30, 2026

Q2 Earnings Roundup: Incyte (NASDAQ:INCY) And The Rest Of The Biotechnology Segment - The Globe and Mail

Sep 30, 2026

INCY or TECH: Which Is the Better Value Stock Right Now? - Zacks Investment Research

Sep 30, 2026

Q2 Earnings Roundup: Incyte (NASDAQ:INCY) And The Rest Of The Biotechnology Segment - TradingView

Sep 30, 2026

Sep 28, 2026

A legal chief with more than 25 years in pharma and biotech joins MiniMed. - Stock Titan

Sep 28, 2026

Mission Bio Showcases Tapestri Across Drug Discovery and Clinical Development at World CDx Summit - Business Wire

Sep 28, 2026

Sep 25, 2026

About 300 people in the U.S. have a disease that causes bone to form in soft tissues. FDA approves a treatment. - Stock Titan

Sep 25, 2026

Sep 22, 2026

Incyte will present research on eczema, vitiligo and painful skin conditions in Vienna - Stock Titan

Sep 22, 2026

Sep 20, 2026

More than 1 million patients have used this skin cream. Partners plan to bring it to Australia. - Stock Titan

Sep 20, 2026

Sep 15, 2026

Incyte Genomics Inc (INCY) Revenue 2025: $5.1B, up 21.2% - Stock Titan

Sep 15, 2026

Incyte Genomics Inc (INCY) Total Assets 2025: $7.0B, up 27.8% - Stock Titan

Sep 15, 2026

Incyte Genomics Inc (INCY) EPS 2025: $6.41, up 4173.3% - Stock Titan

Sep 15, 2026

Incyte Genomics Inc (INCY) Net Income 2025: $1.3B, up 3846.9% - Stock Titan

Sep 15, 2026

Sep 14, 2026

Incyte (INCY): 3 Reasons We Love This Stock - Yahoo Finance

Sep 14, 2026

Sep 11, 2026

Here's How Much $1000 Invested In Incyte 20 Years Ago Would Be Worth Today - Benzinga

Sep 11, 2026

Cantor Fitzgerald reiterates Neutral on Incyte stock after conference - Investing.com

Sep 11, 2026

Profitable Biotech Incyte Stock Forms Handle Amid Strong Institutional Accumulation - Investor's Business Daily

Sep 11, 2026

Cantor Fitzgerald reiterates Neutral on Incyte stock after conference By Investing.com - Investing.com South Africa

Sep 11, 2026

Sep 10, 2026

Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch

Sep 10, 2026

Incyte at Cantor conference: pipeline advances, post-Jakafi plan - investing.com

Sep 10, 2026

Incyte Announces Funding of MINJUVI® (tafasitamab) for patients with Relapsed or Refractory Follicular Lymphoma through Ontario's FAST Program - Yahoo Finance

Sep 10, 2026

Sep 09, 2026

Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch

Sep 09, 2026

Incyte at Wells Fargo healthcare conference: pipeline aims to reshape growth - Investing.com India

Sep 09, 2026

Incyte at Wells Fargo healthcare conference: pipeline aims to reshape growth - investing.com

Sep 09, 2026

Incyte at Wells Fargo healthcare conference: pipeline aims to reshape growth - Investing.com UK

Sep 09, 2026

Sep 08, 2026

Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch

Sep 08, 2026

Incyte (NASDAQ:INCY) Combines High Growth Momentum with a Breakout Setup - ChartMill

Sep 08, 2026

Sep 04, 2026

Incyte Corp. (INCY) Peer Comparison – Compare with Others - Value Research

Sep 04, 2026

Incyte Corp. (INCY) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research

Sep 04, 2026

Incyte (INCY) Institutional Ownership 2026 $INCY - MarketBeat

Sep 04, 2026

Sep 03, 2026

Incyte Corp. (INCY) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com

Sep 03, 2026

2 Profitable Stocks with Impressive Fundamentals and 1 We Brush Off - The Globe and Mail

Sep 03, 2026

Sep 02, 2026

Incyte Corp. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch

Sep 02, 2026

Sep 01, 2026

Incyte Corp. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch

Sep 01, 2026

H.C. Wainwright reiterates Incyte stock rating on Medicaid pricing deal - Investing.com

Sep 01, 2026

Incyte to Present at Upcoming Investor Conferences - Yahoo Finance

Sep 01, 2026

BMO reiterates Incyte stock rating on CMS pricing agreement - Investing.com

Sep 01, 2026

Ähnlich wie INCY

Incyte Corp (INCY)

Incyte Corp Aktie (INCY) Unternehmensprofil

INCY vs. VRTX, REGN, MRNA, ARGX, ONC vergleichen

Incyte Corp Aktie (INCY) Hochstufungen & Herabstufungen

Finanzdaten der Incyte Corp-Aktie (INCY)

Umsatz

Nettogewinn

Free Cashflow

ENV

Incyte Corp-Aktie (INCY) Insiderhandel

Incyte Corp Aktie (INCY) Neueste Nachrichten

MTAK Price Today: Market Technology Acquisition Corp. Stock Price, Quote & Chart | MEXC - MEXC

Incyte & Genmab Collaborate to Develop a New Colorectal Cancer Therapy - Zacks Investment Research

An experimental drug combination showed a 71% response rate in colorectal cancer. - Stock Titan

Incyte Corp. Company & People | INCY - Barron's

Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 - Via TT

Incyte (NasdaqGS:INCY) Stock Price - Simply Wall Street

Incyte Corp. Research & Ratings | INCY - Barron's

Incyte Corp. Advanced Charts | INCY - Barron's

Incyte Corp. Financials | INCY - Barron's

Incyte plans to publish third-quarter results at 7 a.m. Oct. 29, then hold a call at 8. - Stock Titan

Incyte Corporation (INCY) Stock Forecasts - Yahoo Finance

Incyte Corp. Stock Grades | INCY - Barron's

Form 4 Incyte Corporation For: 2 October By Investing.com - Investing.com Canada

Q2 Earnings Roundup: Incyte (NASDAQ:INCY) And The Rest Of The Biotechnology Segment - Yahoo Finance

Q2 Earnings Roundup: Incyte (NASDAQ:INCY) And The Rest Of The Biotechnology Segment - The Globe and Mail

INCY or TECH: Which Is the Better Value Stock Right Now? - Zacks Investment Research

Q2 Earnings Roundup: Incyte (NASDAQ:INCY) And The Rest Of The Biotechnology Segment - TradingView

A legal chief with more than 25 years in pharma and biotech joins MiniMed. - Stock Titan

Mission Bio Showcases Tapestri Across Drug Discovery and Clinical Development at World CDx Summit - Business Wire

About 300 people in the U.S. have a disease that causes bone to form in soft tissues. FDA approves a treatment. - Stock Titan

Incyte will present research on eczema, vitiligo and painful skin conditions in Vienna - Stock Titan

More than 1 million patients have used this skin cream. Partners plan to bring it to Australia. - Stock Titan

Incyte Genomics Inc (INCY) Revenue 2025: $5.1B, up 21.2% - Stock Titan

Incyte Genomics Inc (INCY) Total Assets 2025: $7.0B, up 27.8% - Stock Titan

Incyte Genomics Inc (INCY) EPS 2025: $6.41, up 4173.3% - Stock Titan

Incyte Genomics Inc (INCY) Net Income 2025: $1.3B, up 3846.9% - Stock Titan

Incyte (INCY): 3 Reasons We Love This Stock - Yahoo Finance

Here's How Much $1000 Invested In Incyte 20 Years Ago Would Be Worth Today - Benzinga

Cantor Fitzgerald reiterates Neutral on Incyte stock after conference - Investing.com

Profitable Biotech Incyte Stock Forms Handle Amid Strong Institutional Accumulation - Investor's Business Daily

Cantor Fitzgerald reiterates Neutral on Incyte stock after conference By Investing.com - Investing.com South Africa

Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch

Incyte at Cantor conference: pipeline advances, post-Jakafi plan - investing.com

Incyte Announces Funding of MINJUVI® (tafasitamab) for patients with Relapsed or Refractory Follicular Lymphoma through Ontario's FAST Program - Yahoo Finance

Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch

Incyte at Wells Fargo healthcare conference: pipeline aims to reshape growth - Investing.com India

Incyte at Wells Fargo healthcare conference: pipeline aims to reshape growth - investing.com

Incyte at Wells Fargo healthcare conference: pipeline aims to reshape growth - Investing.com UK

Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch

Incyte (NASDAQ:INCY) Combines High Growth Momentum with a Breakout Setup - ChartMill

Incyte Corp. (INCY) Peer Comparison – Compare with Others - Value Research

Incyte Corp. (INCY) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research

Incyte (INCY) Institutional Ownership 2026 $INCY - MarketBeat

Incyte Corp. (INCY) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com

2 Profitable Stocks with Impressive Fundamentals and 1 We Brush Off - The Globe and Mail

Incyte Corp. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch

Incyte Corp. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch

H.C. Wainwright reiterates Incyte stock rating on Medicaid pricing deal - Investing.com

Incyte to Present at Upcoming Investor Conferences - Yahoo Finance

BMO reiterates Incyte stock rating on CMS pricing agreement - Investing.com

Ähnlich wie INCY